Rxelite Stock Fundamentals
| RXEI Stock | USD 0.0001 0.00 0.00% |
RxElite fundamentals help investors to digest information that contributes to RxElite's financial success or failures. It also enables traders to predict the movement of RxElite Stock. The fundamental analysis module provides a way to measure RxElite's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to RxElite stock.
As of now, RxElite's Research Development is increasing as compared to previous years. The RxElite's current Total Operating Expenses is estimated to increase to about 16 M, while Selling General Administrative is projected to decrease to under 5.6 M.
RxElite | Select Account or Indicator |
RxElite Company Return On Equity Analysis
RxElite's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current RxElite Return On Equity | -2.94 |
Most of RxElite's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RxElite is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
RxElite Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for RxElite is extremely important. It helps to project a fair market value of RxElite Stock properly, considering its historical fundamentals such as Return On Equity. Since RxElite's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of RxElite's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of RxElite's interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
RxElite Total Stockholder Equity
Total Stockholder Equity |
|
As of now, RxElite's Total Stockholder Equity is increasing as compared to previous years.
Based on the latest financial disclosure, RxElite has a Return On Equity of -2.9354. This is 87.75% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
RxElite Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining RxElite's current stock value. Our valuation model uses many indicators to compare RxElite value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across RxElite competition to find correlations between indicators driving RxElite's intrinsic value. More Info.RxElite is rated fourth in return on equity category among its peers. It is rated third in return on asset category among its peers . As of now, RxElite's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the RxElite's earnings, one of the primary drivers of an investment's value.RxElite Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RxElite's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of RxElite could also be used in its relative valuation, which is a method of valuing RxElite by comparing valuation metrics of similar companies.RxElite is currently under evaluation in return on equity category among its peers.
RxElite Fundamentals
| Return On Equity | -2.94 | ||||
| Return On Asset | -0.38 | ||||
| Profit Margin | (2.80) % | ||||
| Operating Margin | (0.97) % | ||||
| Current Valuation | 35.91 K | ||||
| Price To Book | 0.01 X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 2.81 M | ||||
| Gross Profit | 1.2 M | ||||
| EBITDA | (11.55 M) | ||||
| Net Income | (17.17 M) | ||||
| Cash And Equivalents | 1.35 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 256.19 K | ||||
| Debt To Equity | 0.51 % | ||||
| Current Ratio | 0.71 X | ||||
| Book Value Per Share | 0.12 X | ||||
| Cash Flow From Operations | (13.37 M) | ||||
| Earnings Per Share | (0.03) X | ||||
| Number Of Employees | 47 | ||||
| Beta | 37.97 | ||||
| Market Capitalization | 35.91 K | ||||
| Total Asset | 21.27 M | ||||
| Retained Earnings | (28.64 M) | ||||
| Net Asset | 21.27 M |
About RxElite Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze RxElite's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RxElite using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RxElite based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 2.5 M | 2.4 M | |
| Cost Of Revenue | 2.4 M | 2.3 M | |
| Research And Ddevelopement To Revenue | 1.01 | 0.90 | |
| Capex To Revenue | 0.59 | 0.62 | |
| Revenue Per Share | 0.05 | 0.09 | |
| Ebit Per Revenue | 3.93 | 4.13 |
Currently Active Assets on Macroaxis
When determining whether RxElite offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of RxElite's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rxelite Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rxelite Stock:Check out RxElite Piotroski F Score and RxElite Altman Z Score analysis. For more detail on how to invest in RxElite Stock please use our How to Invest in RxElite guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of RxElite. If investors know RxElite will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about RxElite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share | Quarterly Revenue Growth 3.321 | Return On Assets | Return On Equity |
The market value of RxElite is measured differently than its book value, which is the value of RxElite that is recorded on the company's balance sheet. Investors also form their own opinion of RxElite's value that differs from its market value or its book value, called intrinsic value, which is RxElite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because RxElite's market value can be influenced by many factors that don't directly affect RxElite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between RxElite's value and its price as these two are different measures arrived at by different means. Investors typically determine if RxElite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, RxElite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.